uniQure schedules Type A FDA meeting for accelerated approval of AMT-130 in Huntington's disease

uniQure N.V.

Type A meeting with FDA scheduled to discuss BLA data package for accelerated approval of AMT-130 (Huntington's disease gene therapy).
CEO Matt Kapusta emphasized commitment to constructive dialogue and timely resolution for patients with high unmet need.
Regulatory update expected after receipt of official meeting minutes from the FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.